Search Results (469)

Benzothiazole derivatives have emerged as being highly significant in drug discovery due to their versatile biological activities and structural adaptability. Incorporating nitrogen and sulfur, this fused heterocyclic scaffold exhibits wide-ranging pharmacological properties, including anticancer, antimicrobial, anti-inflammatory, antidiabetic, neuroprotective, and diagnostic applications. A diverse set of clinically approved and investigational compounds, such as flutemetamol for Alzheimer’s diagnosis, riluzole for ALS, and quizartinib for AML, illustrates the scaffold’s therapeutic potential in varied applications. These agents act via mechanisms such as enzyme inhibition, receptor modulation, and amyloid imaging, demonstrating the scaffold’s high binding affinity and target specificity. Advances in synthetic strategies and our understanding of structure–activity relationships (SARs) continue to drive the development of novel benzothiazole-based therapeutics with improved potency, selectivity, and safety profiles. We also emphasize recent in vitro and in vivo studies, including drug candidates in clinical trials, to provide a comprehensive perspective on the therapeutic potential of benzothiazole-based compounds in modern drug discovery. This review brings together recent progress to help guide the development of new benzothiazole-based compounds for future therapeutic applications. Full article

The ongoing threat of antimicrobial-resistant pathogens has intensified the need for new antimicrobial agents, making the discovery of novel natural products crucial. This study focuses on the isolation and characterization of a novel Streptomyces species from the Anjar region in Lebanon, an area rich in microbial diversity that is largely unexplored for its biotechnological potential. Soil samples were collected and processed, leading to the isolation of Streptomyces strain ANJ10. Comprehensive morphological, physiological, and genomic analyses were conducted, including whole-genome sequencing (WGS) to identify biosynthetic gene clusters (BGCs) and broth microdilution (BMD) assays to evaluate antimicrobial activity. The ANJ10 genome revealed 42 BGCs, significantly more than the average number in Streptomyces species, suggesting a high potential for secondary metabolite production. Phylogenetic analysis confirmed ANJ10 as a novel species, and BMD assays demonstrated its strong antimicrobial activity against several gram-negative pathogens, specifically, Acinetobacter baumannii. These findings underscore the potential of this strain as a significant source of new antimicrobial compounds, reinforcing the importance of exploring underexploited environments like Lebanon for microbial bioprospecting. Full article

Background: The global spread of antibiotic-resistant bacteria presents a major public health challenge and necessitates the development of innovative antimicrobial agents. Artificial intelligence (AI)-driven drug discovery has recently enabled the repurposing of existing compounds with novel therapeutic potential. Halicin, originally developed as an anti-diabetic molecule, has been identified through AI screening as a promising antibiotic candidate due to its broad-spectrum activity, including efficacy against multidrug-resistant pathogens. Methods: In this study, the antibacterial activity of halicin was evaluated against a range of clinically relevant multidrug-resistant bacterial strains. Bacterial isolates were first characterized using the agar disk diffusion method with a panel of 22 conventional antibiotics to confirm resistance profiles. The minimum inhibitory concentration (MIC) of halicin was then determined for selected isolates, including Escherichia coli ATCC^® 25922™ and Staphylococcus aureus ATCC^® 29213™, using broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Results: Halicin demonstrated notable antibacterial activity, with MIC values of 16 μg/mL and 32 μg/mL against E. coli ATCC^® 25922™ and S. aureus ATCC^® 29213™, respectively. A dose-dependent inhibition of bacterial growth was observed for the majority of tested isolates, except for Pseudomonas aeruginosa, which exhibited intrinsic resistance. This lack of susceptibility is likely related to reduced outer membrane permeability, limiting the intracellular accumulation of halicin. Conclusions: Our findings support the potential of halicin as a novel antimicrobial agent for the treatment of infections caused by antibiotic-resistant bacteria. However, further investigations, including pharmacokinetic, pharmacodynamic, and toxicity studies, are essential to assess its clinical safety and therapeutic applicability. Full article

Plasmodium falciparum is the causative agent of malaria, a parasitic disease that affects millions of people in terms of prevalence and is associated with hundreds of thousands of deaths. Current antimalarial medications, in addition to exhibiting moderate to serious adverse reactions, are not efficacious enough due to factors such as drug resistance. In silico approaches can speed up the discovery and design of new molecules with wide-spectrum antimalarial activity. Here, we report a unified computational methodology combining a perturbation theory machine learning model based on multilayer perceptron networks (PTML-MLP) and the fragment-based topological design (FBTD) approach for the prediction and design of novel molecules virtually exhibiting versatile antiplasmodial activity against diverse P. falciparum strains. Our PTML-MLP achieved an accuracy higher than 85%. We applied the FBTD approach to physicochemically and structurally interpret the PTML-MLP, subsequently extracting several suitable molecular fragments and designing new drug-like molecules. These designed molecules were predicted as multi-strain antiplasmodial inhibitors, thus representing promising chemical entities for future synthesis and biological experimentation. The present work confirms the potential of combining PTML modeling and FBTD for early antimalarial drug discovery while opening new horizons for extended computational applications for antimicrobial research and beyond. Full article

The discovery of new microbial metabolites is essential to combat the alarming rise in antimicrobial resistance and to meet emerging medical needs. This work critically reviews current strategies for identifying antimicrobial compounds, emphasizing the potential of microorganisms as a rich source of bioactive secondary metabolites. This review explores innovative methods, such as investigating extreme environments where adverse conditions favor the emergence of unique metabolites; developing techniques, like the iChip, to cultivate previously uncultivable bacteria; using metagenomics to analyze complex samples that are difficult to isolate; and integrates artificial intelligence to accelerate genomic mining, structural prediction, and drug discovery optimization processes. The importance of overcoming current challenges, such as replicating findings, low research investment, and the lack of adapted collection technologies, is also emphasized. Additionally, this work analyzes the crucial role of bacterial resistance and the necessity of a holistic approach involving new technologies, sustained investment, and interdisciplinary collaboration. This work emphasizes not only the current state of metabolite discovery but also the challenges that must be addressed to ensure a continuous flow of new therapeutic molecules in the coming decades. Full article

The Leontopodium R.Br. ex Cass. taxa have been extensively phytochemically researched for their beneficial properties by the pharmaceuticals industry. These species have been used as remedies since ancient times, and their usage in traditional medicine has been a source of inspiration for current research. As a result, a comprehensive review study concerning the bioactivities of secondary metabolites belonging to Leontopodium species would be of great interest. Our research shows that the majority of studies addressed the anti-inflammatory activity, and the most studied compound was leoligin, a lignan with cardioprotective properties. The diverse range of bioactivities were intricately linked to the abundance of secondary metabolites, which conferred effective antimicrobial activity, antioxidant properties, the anti-neurodegenerative potential due to improvements in cholinergic transmission, the anti-tumour effects on various cancer cell lines, particularly breast and lung cancer, and the hypoglycaemic and hepatoprotective properties. All these important bioactivities also recommend Leontopodium taxa as a valuable source for the discovery of new drugs. Full article

Dengue virus (DENV) remains a critical global health challenge, with no approved antiviral treatments currently available. The growing prevalence of DENV infections highlights the urgent need for effective therapeutics. Antiviral peptides (AVPs) have gained significant attention due to their potential to inhibit viral replication. However, traditional drug discovery methods are often time-consuming and resource-intensive. Advances in artificial intelligence, particularly deep generative models (DGMs), offer a promising approach to accelerating AVP discovery. This report provides a comprehensive assessment of the role of DGMs in identifying novel AVPs for DENV. It presents an extensive survey of existing antimicrobial and AVP datasets, peptide sequence feature representations, and the integration of DGMs into computational peptide design. Additionally, in vitro and in silico screening data from previous studies highlight the therapeutic potential of AVPs against DENV. Variational autoencoders and generative adversarial networks have been extensively documented in the literature for their applications in AVP generation. These models have demonstrated a remarkable capacity to generate diverse and structurally viable compounds, significantly expanding the repertoire of potential antiviral candidates. Additionally, this report assesses both the strengths and limitations of DGMs, providing valuable insights for guiding future research directions. As a data-driven and scalable framework, DGMs offer a promising avenue for the rational design of potent AVPs targeting DENV and other emerging viral pathogens, contributing to the advancement of next-generation therapeutic strategies. Full article

The distribution of Amaryllidaceae alkaloids, with a focus on their chemodiversity, has been reported previously, but not at a genera-wide diversity level. This review provides a comprehensive survey of the occurrence of Amaryllidaceae alkaloids across the genera of the Amaryllidaceae family. This survey is taxonomically guided by the National Center for Biotechnology Information (NCBI) Taxonomy Browser, with targeted keyword searches conducted in the Chemical Abstracts Service (CAS) SciFinder-n and PubMed. The family Amaryllidaceae comprises over 1214 species across three subfamilies: Agapanthoideae (1 genus, 5 species), Allioideae (3 genera plus 11 subgenera, 617 species), and Amaryllidoideae (58 genera plus 13 subgenera, 592 species). Amaryllidaceae alkaloids have been identified exclusively in 36 of the 58 genera and 6 of the 13 subgenera within the Amaryllidoideae subfamily. To date, more than 600 Amaryllidaceae alkaloids have been isolated, predominantly from this subfamily—hence the designation “Amaryllidaceae alkaloids”. These alkaloids display a wide spectrum of biological activities, including acetylcholinesterase inhibition, anti-inflammatory, antioxidant, antimicrobial, antidiabetic, and anticancer effects. A notable example is galanthamine (also known as galantamine), an FDA-approved drug marketed under the brand names Reminyl™ (Janssen Research Foundation, Beerse, Belgium, 2001) and Razadyne™ (Johnson & Johnson Pharmaceutical Research, New Brunswick, NJ, USA, 2004) for the treatment of mild to moderate Alzheimer’s disease, due to its potent acetylcholinesterase-inhibitory activity. Galanthamine has been isolated from species belonging to the genera Cyrtanthus, Galanthus, Leucojum, Lycoris, Narcissus, Ungernia, Chlidanthus, Crinum, Eucharis, Eustephia, Pancratium, and Phaedranassa. Lycorine is another widely distributed alkaloid found across multiple genera, and it has been extensively studied for its diverse bioactivities. Given the remarkable chemical diversity and bioactivity of Amaryllidaceae alkaloids, along with the many underexplored genera and species, further research into Amaryllidaceae species and their alkaloids is strongly warranted to support the discovery and development of novel therapeutic agents. Full article

Microorganisms play a dual role in human health, serving as both essential allies and serious threats. Their association with infections led to the development of antimicrobials like penicillin, which revolutionized medicine. However, the emergence of antimicrobial resistance (AMR) has created a global health crisis, rendering many treatments ineffective due to pathogen mutations and acquired resistance mechanisms, particularly among ESKAPE pathogens. This resistance increases morbidity, mortality, and healthcare costs, exacerbated by antibiotic overuse and globalization. Biofilms and sepsis further complicate treatment. Addressing AMR requires new therapies, rational antibiotic use, and innovative approaches for drug discovery. Coordinated global action is essential to ensure future access to effective treatments. Antimicrobial peptides (AMPs) derived from Boana species (Anura, Hylidae) represent a promising alternative in the fight against AMR. These peptides exhibit activity against multidrug-resistant pathogens. Unlike conventional antibiotics, Boana peptides act through a broad mechanism that limits resistance development. Their ability to disrupt bacterial membranes and modulate immune responses makes them ideal candidates for the development of new treatments. These peptides may offer valuable alternatives for treating resistant infections and addressing the global AMR crisis. Full article

Antimicrobial resistance represents one of the most critical public health challenges of the 21st century. The emergence of multidrug resistance (MDR) in bacterial and fungal pathogens to diverse chemical agents severely impedes the effective treatment of diseases such as cancer and systemic infections. The rapid escalation of microbial resistance underscores the urgent need for the discovery of novel antimicrobial agents and innovative approaches to drug development. In both clinical and industrial contexts, the identification of new antibiotics and antifungals remains pivotal for pathogen control. Current research efforts focus on the development of alternative formulations that offer high efficacy, reduced resistance potential, minimal side effects, and synergistic interactions, particularly those derived from natural sources. Filamentous fungi originating from extreme environments have evolved to thrive under harsh conditions, making them promising reservoirs of bioactive metabolites with unique structural and functional properties. These fungi exhibit potent antimicrobial activity through diverse mechanisms that disrupt essential cellular processes in pathogens. Despite their remarkable potential, the bioprospecting of extremophilic filamentous fungi for drug development remains underexplored. This highlights the necessity for expanded research into the efficacy and safety of their derived compounds. This review aims to emphasize the capacity of extremophilic fungi to produce antimicrobial agents, elucidate resistance mechanisms, characterize fungal bioactive extracts, and analyze their molecular actions in the context of their extreme ecological niches. Full article

This review critically explores the pharmacological potential of four traditionally significant medicinal plants—Phoenix dactylifera, Solanum lycopersicum, Withania somnifera, and Trigonella foenum-graecum—with a specific focus on their antidiabetic, cardioprotective, and antimicrobial properties. In light of the escalating global burden of chronic metabolic diseases and the alarming rise in antimicrobial resistance, there is an urgent demand for alternative, sustainable therapeutic strategies. Drawing upon both ethnopharmacological evidence and contemporary biomedical research, this study identifies and characterizes the key bioactive constituents responsible for the observed therapeutic effects. These phytochemicals include flavonoids, phenolic acids, alkaloids, and saponins, which modulate metabolic pathways, exert antioxidative and anti-inflammatory effects, and inhibit microbial proliferation. A systematic literature search was conducted across PubMed, Web of Science, and Scopus databases, covering peer-reviewed articles published between 2000 and 2025. Inclusion criteria emphasized both in vitro and in vivo experimental models to provide a holistic understanding of molecular mechanisms and biological efficacy. Importantly, this review does not propose these plant extracts as direct substitutes for clinically established therapies but rather as potential complementary agents or sources of novel compounds for future drug development. This integrative approach underscores the relevance of traditional medicinal knowledge in guiding the discovery of plant-based therapeutics. It highlights these species as promising candidates for innovative health interventions in the context of modern biomedicine and global public health. Full article

Increasing multidrug resistance in Neisseria gonorrhoeae poses a serious and escalating public health crisis. The World Health Organization has classified N. gonorrhoeae as a high-priority pathogen for developing new antimicrobials. Natural products provide a promising avenue for antimicrobial discovery, serving as direct therapeutic agents or prototypes for novel drug development. Among these, gibbilimbol B, a compound isolated from Piper malacophyllum, is particularly attractive due to its biological potential and simple structure. In this study, eight synthetic phenylalkylamides (1–8) inspired by gibbilimbol B were synthesized and evaluated for their antibacterial activity against N. gonorrhoeae. The in vitro bacterial assays revealed that these compounds exhibit notable antibacterial activity, including against resistant strains selected from the CDC/FDA antimicrobial panel (strains AR-173, AR-174, AR-187, and AR-200). All synthesized compounds demonstrated superior efficacy in killing N. gonorrhoeae compared to gibbilimbol B. Notably, compound 8 [(E)-4-chloro-N-(oct-4-en-1-yl)benzamide] showed an MBC50 of 6.25 µM, representing a four-fold improvement in bactericidal activity over the natural compound. This study represents the first exploration of gibbilimbol analogs for antibacterial applications, highlighting the novelty of the work and paving the way for the development of new antibacterial agents. Full article

Background: Horwoodia dicksoniae Turrill. (Brassicaceae) and Stipa capensis Thunb. (Poaceae) are commonly grown in the eastern region of Saudi Arabia. Methods: This study evaluated the antibacterial and antifungal potential of these plants. H. dicksoniae extract was further subjected to antioxidant, anticancer, GC-MS, LC-MS/MS, and in silico analyses. Results: H. dicksoniae extract presented a higher antimicrobial efficiency than S. capensis extract by effectively inhibiting the growth of Staphylococcus aureus, Escherichia coli, Proteus vulgaris, Bacillus subtilis, and Candida albicans. H. dicksoniae ethanolic extract also demonstrated promising antioxidant and anticancer properties against the human colon cancer cell line HCT-116. GC-MS analysis revealed the presence of 12 natural compounds in the H. dicksoniae extract, whereas LC-MS/MS analysis revealed 19 different compounds in negative ion mode and 25 in positive ion mode. Furthermore, the presence of bioactive compounds in the H. dicksoniae extract, such as flavonoids (acacetin and hesperetin) and caffeic acid, confirmed the observed antibacterial, antifungal, antioxidant, and anticancer activities. Molecular docking revealed promising interactions between various bioactive compounds and target proteins associated with antimicrobial, antioxidant, and anticancer activities. Conclusions: This study is the first to report GC-MS and LC-MS/MS analyses of H. dicksoniae ethanolic extract. The findings provide valuable insights into the potential mechanisms and therapeutic applications of the identified bioactive compounds. Thus, the present work can serve as a platform for the isolation of natural compounds from H. dicksoniae extract, which may play a significant role in the discovery and design of new drugs for the treatment of human diseases. Full article

This review discusses natural and synthetic azo compounds found in bacteria, fungal endophytes, fungi, plants, and invertebrates. More than 100 of these compounds have demonstrated significant pharmacological activity, including antitumor, antimicrobial, and antibacterial effects. Using mathematical algorithms and the PASS program, researchers predict new potential applications based on their structure–activity relationships. This review emphasizes the importance of natural azo compounds as promising drug prototypes and key players in drug discovery. It also explores the synthesis and degradation of azo dyes and their potential uses in medicine, food, cosmetics, and related fields. Additionally, the role of microorganisms in producing natural azo compounds and their synthetic counterparts is examined, showcasing their potential in drug development and human health advancements. Full article

Antimicrobial resistance (AMR) is a global health threat, with methicillin-resistant Staphylococcus aureus (MRSA) being one of the major resistant pathogens. This study reports the isolation of a novel mangrove-derived bacterium, Virgibacillus chiguensis FN33, as identified through genome analysis and the discovery of a new anionic antimicrobial peptide (AMP) exhibiting anti-MRSA activity. The AMP was composed of 23 amino acids, which were elucidated as NH₃-Glu-Gly-Gly-Cys-Gly-Val-Asp-Thr-Trp-Gly-Cys-Leu-Thr-Pro-Cys-His-Cys-Asp-Leu-Phe-Cys-Thr-Thr-COOH. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for MRSA were 8 µg/mL and 16 µg/mL, respectively. FN33 AMP induced cell membrane permeabilization, suggesting a membrane-disrupting mechanism. The AMP remained stable at 30–40 °C but lost activity at higher temperatures and following exposure to proteases, surfactants, and extreme pH. All-atom molecular dynamics simulations showed that the AMP adopts a β-sheet structure upon membrane interaction. These findings suggest that Virgibacillus chiguensis FN33 is a promising source of novel antibacterial agents against MRSA, supporting alternative strategies for drug-resistant infections. Full article